Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

详细信息    查看全文

• 作者：Alessandro D. Santin^a ; ^{alessandro.santin@yale.edu} ; Stefania Bellone^a ; Natalia Buza^b ; Peter E. Schwartz^a
• 关键词：Uterine serous carcinoma ; Trastuzumab-emtansine ; HER2/neu
• 刊名：Gynecologic Oncology Reports
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：19
• 期：Complete
• 页码：10-12
• 全文大小：759 K
• 卷排序：19

文摘

USC patients have limited therapeutic options when the disease becomes resistant to chemotherapy. About 35% of USC overexpress the HER2/neu receptor at 3 + level by IHC and/or are c-erbB2 gene amplified. Trastuzumab emtansine (T-DM1, Kadcyla) is a novel antibody-drug conjugate. T-DM1 may represent a novel treatment modality in USC patients with recurrent, HER2/neu + disease.